Early metformin initiation after COVID-19 infection is associated with a substantially lower 1-year risk for long COVID in adults with overweight or obesity, according to study results published in ...

The company has announced positive data from the ACHIEVE-2 and ACHIEVE-5 trials, with both meeting all their primary and key ...

Eli Lilly announces positive results from phase 3 ACHIEVE-2 & ACHIEVE-5 trials of orforglipron versus dapagliflozin in adults with type 2 diabetes: Indianapolis Thursday, October ...

New Delhi, October 16 (IANS): US researchers have identified a gene on the X chromosome that drives inflammation in the ...

Multiple sclerosis and Alzheimer's disease each affect women more often than men, about two to three times as often, ...

Eli Lilly and Company's strong Phase 3 diabetes drug results boost its GLP-1 franchise. Click for my updated look at LLY ...

New research by UCLA Health has identified a sex-chromosome linked gene that drives inflammation in the female brain, ...

Eli Lilly’s oral GLP-1 therapy, orforglipron, met all primary and key secondary endpoints in the Phase III ACHIEVE-2 and ACHIEVE-5 studies, showing significant A1C reduction, weight loss, and ...

New research by UCLA Health has identified a sex-chromosome linked gene that drives inflammation in the female brain, ...

A new study has pinpointed why women are more likely to develop Alzheimer's Disease - and it all comes down to sex ...

After beating Novo Nordisk’s semaglutide last month, Lilly’s much anticipated oral candidate orforglipron has taken down AstraZeneca’s Farxiga in a head-to-head trial.